Skip to main content
Article thumbnail
Location of Repository


By Peihong Wu, Guoguang Ren and Guang Ning


Context: Berberine, a natural plant alkaloid, is usually used as an antibiotic drug. The potential glucose-lowering effect of berberine was noted when it was used for diarrhea in diabetic patients. In vitro and in vivo studies have then showed its effects on hyperglycemia and dyslipidemia. Objective: The objective of the study was to evaluate the efficacy and safety of berberine in the treatment of type 2 diabetic patients with dyslipidemia. Design: One hundred sixteen patients with type 2 diabetes and dyslipidemia were randomly allocated to receive berberine (1.0 g daily) and the placebo for 3 months. The primary outcomes were changes in plasma glucose and serum lipid concentrations. Glucose disposal rate (GDR) was measured using a hyperinsulinemic euglycemic clamp to assess insulin sensitivity. Results: In the berberine group, fasting and postload plasma glucose decreased from 7.0 � 0.8 to 5.6 � 0.9 and from 12.0 � 2.7 to 8.9 � 2.8 mM/liter, HbA1c from 7.5 � 1.0 % to 6.6 � 0.7%, triglyceride from 2.51 � 2.04 to 1.61 � 1.10 mM/liter, total cholesterol from 5.31 � 0.98 to 4.35 � 0.96 mM/liter, and low-density lipoprotein-cholesterol from 3.23 � 0.81 to 2.55 � 0.77 mM/liter, with all parameters differing from placebo significantly (P � 0.0001, P � 0.0001, P � 0.0001, P � 0.001, P � 0.0001, and P �0.0001, respectively). The glucose disposal rate was increased after berberine treatmen

Year: 2013
OAI identifier: oai:CiteSeerX.psu:
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.